1. Home
  2. OXSQ vs SPRO Comparison

OXSQ vs SPRO Comparison

Compare OXSQ & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oxford Square Capital Corp.

OXSQ

Oxford Square Capital Corp.

HOLD

Current Price

$1.42

Market Cap

164.9M

Sector

Finance

ML Signal

HOLD

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$1.19

Market Cap

156.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OXSQ
SPRO
Founded
2003
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
164.9M
156.3M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
OXSQ
SPRO
Price
$1.42
$1.19
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.4M
2.0M
Earning Date
04-29-2026
05-13-2026
Dividend Yield
22.83%
N/A
EPS Growth
N/A
111.81
EPS
N/A
N/A
Revenue
N/A
$66,802,000.00
Revenue This Year
$3.61
N/A
Revenue Next Year
N/A
$300.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
39.24
52 Week Low
$1.05
$1.08
52 Week High
$2.42
$3.08

Technical Indicators

Market Signals
Indicator
OXSQ
SPRO
Relative Strength Index (RSI) 45.30 20.75
Support Level $1.26 N/A
Resistance Level $1.43 $2.44
Average True Range (ATR) 0.06 0.16
MACD -0.01 -0.06
Stochastic Oscillator 10.87 9.13

Price Performance

Historical Comparison
OXSQ
SPRO

About OXSQ Oxford Square Capital Corp.

Oxford Square Capital Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize portfolio's total return. Its primary current focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and, to a lesser extent collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. CLO investments may also include warehouse facilities, which are early-stage CLO vehicles intended to aggregate loans that may be used to form the basis of a traditional CLO vehicle. The company may also invest in publicly traded debt and/or equity securities.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: